BRAINSTORM CELL THERAPUTC (BCLI) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 8, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BCLI SEC filings page.
This page shows BRAINSTORM CELL THERAPUTC (BCLI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The reported business remains development-led: shrinking research spending has not stopped operating cash needs from being funded externally.
From FY2023 to FY2024, operating cash outflow fell from$20.5M to$9.1M , but the business still did not generate cash internally. Financing inflows of$19.0M and$8.0M moved alongside those outflows, so the improvement reflects a smaller cash requirement rather than self-funding operations.
By FY2025, liabilities exceeded assets:
Research spending fell from
Financial Health Signals
BRAINSTORM CELL THERAPUTC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
BRAINSTORM CELL THERAPUTC's EBITDA was -$3.6M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 41.4% from the same quarter a year earlier.
BRAINSTORM CELL THERAPUTC reported -$3.9M in net income in Q2 2026. This represents a decrease of 32.8% from the same quarter a year earlier. Against the prior quarter it is down 81.2%.
BRAINSTORM CELL THERAPUTC earned -$0.35 per diluted share (EPS) in Q2 2026. This represents a decrease of 2.9% from the same quarter a year earlier.
Not reported for Q2 2026.
Cash & Balance Sheet
BRAINSTORM CELL THERAPUTC held $22K in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
None of these metrics is reported for Q2 2026.
Capital Allocation
BRAINSTORM CELL THERAPUTC invested $963K in research and development in Q2 2026. This represents a decrease of 14.0% from the same quarter a year earlier.
Not reported for Q2 2026.
Not reported for Q2 2026.
BCLI Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'24S-1 | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $963K-14.0% | N/A | N/A | $899K-14.0% | $1.1M+21.5% | N/A | N/A | $1.0M-68.6% |
| SG&A Expenses | $2.6M+82.4% | N/A | N/A | $1.1M-42.7% | $1.5M-29.5% | N/A | N/A | $2.0M-26.0% |
| Operating Income | -$3.6M-40.4% | N/A | N/A | -$2.0M+32.8% | -$2.6M+13.7% | N/A | N/A | -$3.0M+49.5% |
| EBITDA | -$3.6M-41.4% | N/A | N/A | -$2.0M+33.1% | -$2.5M+13.6% | N/A | N/A | -$3.0M+49.9% |
| Interest Expense | $242K-26.7% | N/A | N/A | $59K+9.3% | $330K | N/A | N/A | $54K |
| Net Income | -$3.9M-32.8% | -$2.1M+25.7% | N/A | -$2.1M+22.2% | -$2.9M-14.2% | -$2.9M+15.8% | N/A | -$2.7M-120.9% |
| EPS (Basic) | -$0.35-2.9% | N/A | -$0.20 | -$0.19+62.7% | -$0.34+43.3% | N/A | N/A | -$0.51-13.3% |
| EPS (Diluted) | -$0.35-2.9% | N/A | -$0.20 | -$0.19 | -$0.34 | N/A | N/A | -$0.51 |
| Diluted Shares (Avg) | 11M+28.0% | N/A | N/A | 11M | 9M | N/A | N/A | 5M |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.
BCLI Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'24S-1 | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $788K-69.3% | N/A | $1.0M-44.2% | $1.4M-31.9% | $2.6M-54.8% | $3.6M+6.7% | $1.8M-56.5% | $2.0M-64.4% |
| Current Assets | $316K-79.1% | N/A | $307K-20.3% | $508K+39.6% | $1.5M-60.3% | $2.3M+85.2% | $385K-79.7% | $364K-76.3% |
| Cash & Equivalents | $22K-97.3% | $206K-87.5% | $29K-84.5% | $5K-97.0% | $824K-76.2% | $1.6M+111.0% | $187K-85.6% | $168K-86.3% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | N/A | $0-100.0% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | N/A | $0 |
| Total Liabilities | $12.4M+43.6% | N/A | $11.0M+14.7% | $9.1M+12.3% | $8.6M-6.4% | $11.0M+23.9% | $9.6M+5.8% | $8.1M-2.2% |
| Current Liabilities | $12.4M+45.2% | N/A | $11.0M+22.6% | $9.0M+27.4% | $8.5M+10.9% | $10.9M+59.6% | $9.0M+15.1% | $7.1M+12.0% |
| Non-Current Liabilities | $0-100.0% | N/A | $0-100.0% | $50K-95.0% | $95K-93.7% | $127K-93.9% | $618K-51.2% | $1.0M-48.5% |
| Total Equity | -$11.6M-91.5% | -$11.0M-47.6% | -$10.0M-28.6% | -$7.7M-27.0% | -$6.1M-71.7% | -$7.5M-34.4% | -$7.8M-59.8% | -$6.1M-134.6% |
| Retained Earnings | -$242.9M | N/A | -$236.9M-4.5% | -$234.5M-4.8% | N/A | -$229.5M-5.1% | -$226.6M-5.4% | -$223.7M-6.8% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
BCLI Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'24S-1 | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$895K+74.4% | N/A | N/A | -$1.1M+66.6% | -$3.5M-108.1% | N/A | -$1.0M+68.1% | -$3.3M+48.5% |
| Depreciation & Amortization | $46K-9.8% | N/A | N/A | $48K-18.6% | $51K-20.3% | N/A | N/A | $59K-9.2% |
| Stock-Based Compensation | N/A | N/A | N/A | N/A | N/A | $717K+321.8% | N/A | N/A |
| Financing Cash Flow | $898K-66.8% | N/A | N/A | $313K | $2.7M-38.2% | N/A | $1.1M-68.4% | $0-100.0% |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
BCLI Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Debt-to-Equity, Asset Turnover, FCF Margin.
Note: Shareholder equity is negative (-$10.0M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.03), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| BRAINSTORM CELL THERAPUTC BCLI | FY2025 | N/A | N/A | N/A | $10.1M | — |
| Alzamend Neuro, Inc. ALZN | FY2026 | N/A | -$8.8M | N/A | $6.6M | — |
| TNF Pharmaceuticals, Inc. TNFA | FY2025 | N/A | -$11.6M | N/A | $9.6M | — |
| Adial Pharmaceuticals, Inc ADIL | FY2025 | N/A | N/A | N/A | $11.7M | — |
| HCW Biologics Inc. HCWB | FY2025 | $54K | -$8.0M | N/A | $3.5M | — |
| AIM ImmunoTech Inc. AIM | FY2025 | $88K | -$14.0M | N/A | $7.3M | — |
Where BRAINSTORM CELL THERAPUTC Ranks
Frequently Asked Questions
What are BRAINSTORM CELL THERAPUTC's total assets?
BRAINSTORM CELL THERAPUTC (BCLI) had $1.0M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does BRAINSTORM CELL THERAPUTC spend on research and development?
BRAINSTORM CELL THERAPUTC (BCLI) invested $4.2M in research and development during fiscal year 2025.
What is BRAINSTORM CELL THERAPUTC's current ratio?
BRAINSTORM CELL THERAPUTC (BCLI) had a current ratio of 0.03 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is BRAINSTORM CELL THERAPUTC's P/E ratio?
BRAINSTORM CELL THERAPUTC (BCLI) has no price-to-earnings ratio at the moment: no net income reported. The market capitalization is $10.1M as of Oct 8, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is BRAINSTORM CELL THERAPUTC's price-to-sales ratio?
BRAINSTORM CELL THERAPUTC (BCLI) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $10.1M as of Oct 8, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Why is BRAINSTORM CELL THERAPUTC's debt-to-equity ratio negative or not reported?
BRAINSTORM CELL THERAPUTC (BCLI) has negative shareholder equity of -$10.0M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.